YL217

MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 1 active Small molecule

At a glance

Generic name	YL217
Sponsor	MediLink Therapeutics (Suzhou) Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

YL217 CI brief — competitive landscape report
YL217 updates RSS · CI watch RSS
MediLink Therapeutics (Suzhou) Co., Ltd. portfolio CI